Pharma CEO/Top Executives Global Response to COVID-19_ Virtual Press Briefing
On 19 March 2020, the global biopharmaceutical industry, represented by high-level executives/ CEO’s, took part in a virtual media briefing highlighting industry’s efforts and future commitments to address the current global coronavirus (COVID-19) crisis.
The strong line-up of company representatives marks an important milestone in showcasing the industry’s commitments to accelerate efforts to develop skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world. The severity of the COVID-19 pandemic ...
Postponed: INTERPAT Summer 2020 General Assembly, Boston
INTERPAT's General Assembly which was due to take place in June 2020 in Boston,USA has been postponed due to the current worldwide COVID-19 pandemic situation.
COVID-19
As a science-driven industry that aims to address some of the world’s biggest health care challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the world’s leading biopharmaceutical companies, today confirmed that having already mobilized on an unprecedented scale to respond to the COVID-19 pandemic, they commit to do more. The biopharmaceutical industry commits to accelerate its effort to use its skills, ...
Why intellectual property matters?
Intellectual Property Rights are at the heart of our biopharma industry innovation. They provide key incentives for research and development of new medicines and the improvement of existing ones.
Further resources can be found on the IFPMA website and in the links below:
Why Intellectual Property matters?
Value of Innovation
Sustainable Innovation
New Study: The Economic benefits of strengthening the environment for innovation in Brazil
INTERPAT asked Charles River Associates (CRA) to identify
and quantify the economic benefits from strengthening the
environment for innovation in Brazil. The study was launched in Brasilia on 12th March 2020. The executive summary is available in English and Portuguese. The full report will be published shortly.
Executive Summary in English
Executive Summary in Portuguese
Parliamentary Front in Defense of IP launches activities and pays tribute to INPI
INPI will be celebrating its 50 year anniversary in December 2020 and this important milestone will be addressed in a joint event with the Parliamentary Front in Defense of Intellectual Property and Combating Piracy, on March 12,08h00, in Brasília. (Câmara dos Deputados – Anexo IV 10o Andar – Restaurante Senac)
The Front will hold a breakfast sponsored by INTERPAT, Interfarma and INPI for the launch of its activities this year, when the international CRA study “Value of intellectual property for health and growth – The economic benefits of strengthening the ...
ANNOUNCEMENT: Daren Tang won the nomination for the post of WIPO Director General
WIPO Director General Francis Gurry met on March 5, 2020 with Singapore's Daren Tang, who won the nomination a day earlier for the post of Director General.
WIPO’s Coordination Committee nominated Mr. Tang on March 4, 2020 for the top WIPO job. The WIPO General Assembly will meet in an extraordinary session on May 7-8, 2020, to confirm the Coordination Committee’s nomination.
Mr. Gurry congratulated Mr. Tang, who is the Chief Executive of the Intellectual Property Office of Singapore (IPOS), on his nomination.
Ambassador Tan Hung Seng, Permanent Representative ...
Business Times Article: How Singapore can Lead Biopharma Innovation by INTERPAT & SAPI
INTERPAT supported SAPI (Singapore Association of Pharmaceutical Industries) and contributed to an IP article which highlights the importance of safeguarding Singapore's attractiveness as a biopharmaceutical innovation hub through strong IP protection.
Full Text can be found in our resources by clicking on the following link: Business Times Article and full text.
SAPI VISION:
The Singapore Association of Pharmaceutical Industries (SAPI) aims to make innovative medicine accessible to patients in Singapore. We achieve this through a sustainable ...
Phase One Sino-U.S. Trade Agreement and the Pharmaceutical Industry
On 16 January 2020, China and the United States signed the Economic and Trade Agreement between the Government of the People’s Republic of China and the Government of the United States of America (the Phase One Trade Agreement). The Phase One Trade Agreement includes a chapter on intellectual property aimed at resolving a wide range of key issues relating to intellectual property protection and enforcement, including, among other things, patents, pharmaceutical-related intellectual property and trade secrets. If properly performed and implemented through domestic ...
Medicines – In Support of Follow-On Innovation
25 Sep 2018
In a recent article Professor Christopher Holman (University of Missouri - Kansas City School of Law) again comes out in support of patent protection for the embodiment of follow-on innovation in medicines (Christopher M. Holman, “Inside views: Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection”, Intellectual Property Watch, 21 September 2018). Follow-on pharmaceutical innovation seeks to improve upon existing medicines by a range of alternatives such as offering a safer and more effective variation than the original product ...